Skip to main content

Table 1 Hormonal levels during the course of GnRH analogue pretreatment

From: Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study

Groups n FSH (mIU/ml) LH (mIU/ml) E2 (pg/ml)
1st day 3rd day 5th day 8th day 1st day 3rd day 5th day 8th day 1st day 3rd day 5th day 8th day
Control 12 2.45±0.13 2.43±0.08 2.32±0.06 2.45±0.12 2.77±0.18 2.83±0.19 2.84±0.11 2.90±0.21 252.98±10.29 242.00±12.96 256.60±11.75 246.03±2.80
CDDP 12 2.51±0.16 2.49±0.09 2.41±0.05 2.44±0.14 2.75±0.16 2.83±0.20 2.66±0.32 2.89±0.17 257.71±13.28 252.60±13.90 250.59±11.07 250.98±4.09
GnRHa 12 2.47±0.08 2.71±0.10 2.21±0.07 2.33±0.11 2.87±0.18 3.93±0.13a 2.81±0.27 2.89±0.11 250.34±13.01 265.42±13.49 197.10±13.43 159.63±2.52ab
GnRHant 12 2.33±0.07 2.22±0.11 2.01±0.07 2.14±0.14 2.70±0.12 2.56±0.06 2.42±0.14 2.62±0.08 252.83±11.75 153.04±12.37a 179.87±13.83 151.87±3.43ab
Combination (lng) 12 2.52±0.13 2.29±0.10 2.44±0.05 2.48±0.07 2.96±0.20 2.74±0.05 2.73±0.13 2.64±0.30 247.65±2.80 171.95±7.20a 185.10±13.86 96.57±5.79a
Combination (sht) 12 2.64±0.09 2.33±0.10 2.24±0.25 2.30±0.16 2.88±0.12 2.53±0.17 2.86±0.21 2.75±0.07 260.86±19.57 163.60±17.4a 214.63±11.77 142.21±8.34ab
  1. aP<0.01 vs. control group; bP<0.01 vs. combination (lng) group.
  2. Data are expressed as the mean ± standard error.